MCL1 and acute myeloid leukemia: The MCL1 inhibitors S64315 (NCT03672695), CYC065 (NCT04017546), AMG 176 (NCT03797261), and AZD5991 (NCT03218683) are currently being evaluated in phase 1 or phase 1/2 clinical trials in combination with venetoclax in patients with AML.